Linzess (linaclotide) - Ironwood Pharma, AbbVie
Effect of Age and Age-Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies. (PubMed, Neurogastroenterol Motil) - Sep 8, 2026 - "In this exploratory post hoc analysis, linaclotide was associated with improvements in bowel and abdominal symptoms across age and age-defined menopausal subgroups, with a safety profile consistent with previous studies, suggesting that age and menopausal status did not meaningfully influence treatment outcomes." 
Journal • P2/3 data • P2b data • Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder
http://www.ncbi.nlm.nih.gov/pubmed/42702764
 
Alexander C Ford; Darren M Brenner; James Wu; Kyle Staller; Lesley A Houghton; Lin Chang; Niha Yerneni; Paul Feuerstadt; Sally Higgins; Wendy Chen
 
Sep 8, 2026
 
Prev Next